Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.
Trial locations(5 sites)
China
Beijing Chao-Yang Hospital, Capital Medical University, Beijing, Beijing Municipality The First Affiliated Hospital of Soochow University, Suzhou, Jiangsu Qilu Hospital of Shandong University, Jinan, Shandong Institute of Hematology & Blood Diseases Hospital,Chinese Academy of Medical Sciences, Tianjin, Tianjin Municipality The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang